<DOC>
	<DOC>NCT00890825</DOC>
	<brief_summary>The purpose of this study is to compare the efficacy of AZD6244 in combination with docetaxel versus docetaxel alone in patients with KRAS mutation positive locally advanced or metastatic non small cell lung cancer.</brief_summary>
	<brief_title>Comparison of AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive Non Small Cell Lung Cancer (NSCLC) Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Locally advanced or metastatic non small cell lung cancer (IIIBIV) Failure of first line anticancer therapy (either radiological documentation of disease progression or due to toxicity) in advanced disease or subsequent relapse of disease following first line therapy Tumour sample confirmed as KRAS mutation positive (Note: Sample must be available upon enrolment to ship to AZ appointed central laboratory, or mutation status confirmed locally at AstraZeneca agreed local laboratory using agreed methodology, or mutation status confirmed by an accredited (eg CLIA certified) commercial laboratory (eg Genzyme or Lab 21). Received &gt;1 prior anticancer therapy for advanced or metastatic non small cell lung cancer (excluding radiotherapy) Prior treatment with a MEK inhibitor or any docetaxel containing regimen (prior treatment with paclitaxel is acceptable) Having received an investigational drug within 30 days of starting treatment, or have not recovered from side effects of an investigational drug Brain metastases or spinal cord compression unless asymptomatic, treated and stable off steroids and anticonvulsants for at least 1 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Non small cell lung cancer (NSCLC)</keyword>
	<keyword>KRAS mutation</keyword>
</DOC>